Bio-Rad Laboratories, Inc. Class A Common Stock vs NetEase Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while NetEase Inc trades at $123.31 (market cap $82.75B). The key difference: NetEase Inc is far larger — about 8.8× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and NetEase Inc pays a 2.36% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | NTES | |
|---|---|---|
Market Cap | $9.43B | $82.75B |
Sector | Health | Media |
52-Week High | $356.25 | $159.34 |
52-Week Low | $241.71 | $109.26 |
Enterprise Value | $9.18B | $59.05B |
Dividend Yield | — | 2.36% |
Trailing returns across standard periods
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →